Xinbitai 新必泰 Emtricitabine/Tenofovir 200mg/300mg | Shanghai Desano Generic | GLT

Generic Information: Xinbitai 新必泰 (China)

Xinbitai (新必泰) is Shanghai Desano Pharmaceutical Group's generic combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg, approved by the National Medical Products Administration under approval number 国药准字H20223386. Supplied as thirty film-coated tablets per box, it is a domestically produced alternative to the originator Truvada that has joined China's roster of affordable HIV backbone therapies.

What Is 新必泰 (Xinbitai) Used For?

新必泰 has the same dual role as the reference product. Combined with other antiretrovirals it treats HIV-1 infection in adults and adolescents of at least 35 kg; taken as pre-exposure prophylaxis it lowers the risk of sexually acquired HIV-1 in people who test HIV-negative. Its domestic provenance supports the cost-sensitive, long-duration treatment that chronic HIV management demands.

How Does 新必泰 Work?

Emtricitabine and tenofovir disoproxil fumarate are two reverse transcriptase inhibitors that converge on the same viral enzyme. After intracellular activation, emtricitabine competes with cytidine triphosphate and tenofovir with adenosine triphosphate for insertion into nascent HIV DNA; either substitution stops chain elongation, so viral replication is blocked at its earliest genetic step. The pairing provides a robust, hard-to-escape backbone.

Indications

新必泰 is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, and for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in at-risk, HIV-negative adults and adolescents of at least 35 kg. It is not intended for hepatitis B, and co-infected patients who stop it need monitoring for a possible HBV flare.

Dosage

The recommended dose is one tablet once daily, with or without food, delivering 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate. Renal function is checked before and during treatment, with a longer interval in moderate impairment. PrEP requires a documented negative HIV test before starting and periodic retesting during use to avoid treating an undetected infection with insufficient therapy.

Side Effects

Early side effects commonly include nausea, diarrhea, headache and fatigue, and they tend to resolve with continued dosing. The important long-term risks are kidney injury and bone mineral density loss from the tenofovir disoproxil component, so renal monitoring is standard practice. Rare serious events include lactic acidosis with liver enlargement and hepatitis B flare after stopping the medicine.

Storage

新必泰 tablets are stored at room temperature in the original box, protected from moisture and heat, with no refrigeration required. They ship by ambient-condition courier, and GLT dispatches from a Hong Kong-licensed facility with batch documentation and a certificate of analysis.

Why Choose 新必泰 Through GLT?

Shanghai Desano's NMPA-approved generic offers the emtricitabine/tenofovir backbone at a competitive domestic price, a practical choice for patients and programs that prioritize affordable, continuous supply. GLT's Hong Kong base and China-focused sourcing make this product accessible to overseas buyers with full documentation and traceability.

How to Order

To order 新必泰 (Xinbitai, emtricitabine/tenofovir disoproxil fumarate) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We confirm stock, pack options and delivery timelines to your country, and dispatch from a Hong Kong-licensed facility.

FAQ

Is 新必泰 a generic of Truvada? Yes — it contains the same emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg combination, NMPA-approved.

What approval number does it carry? It is registered in China under 国药准字H20223386, granted to Shanghai Desano Pharmaceutical Group.

Is it for treatment or prevention? Both — it treats HIV-1 in combination therapy and lowers acquisition risk as PrEP in HIV-negative people.